The use of 20% subcutaneous immunoglobulin replacement therapy in patients with B cell non-Hodgkin’s lymphoma with humoral immune dysfunction after treatment with rituximab.
The use of 20% subcutaneous immunoglobulin replacement therapy in patients with B cell non-Hodgkin’s lymphoma with humoral immune dysfunction after treatment with rituximab.
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now